Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
暂无分享,去创建一个
Susan M. Chang | Nicholas J Vogelzang | J. V. Von Roenn | M. Kris | J. Temel | P. Janne | S. Adams | W. Tap | W. Samlowski | C. Aghajanian | N. Vogelzang | A. Seidman | A. Ko | B. Roth | J. Patel | G. Masters | Z. Dreyer | Mark G Kris | Andrew D Seidman | Carol Aghajanian | William D Tap | Andrew H Ko | Jennifer S Temel | Jamie H Von Roenn | S. Benowitz | Jyoti D Patel | Sylvia Adams | Wolfram E Samlowski | Pasi A Janne | Bruce J Roth | Steven I Benowitz | Susan Marina Chang | Zoann Eckert Dreyer | Greg A Masters | Olatoyosi Odenike | O. Odenike
[1] K. Aldape,et al. RTOG 0525: Molecular correlates from a randomized phase III trial of newly diagnosed glioblastoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] G. Shapiro,et al. Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Hauschild,et al. Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] F. Staff. FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer , 2011 .
[5] S. Wacholder,et al. Cervical cancer risk for 330,000 women undergoing concurrent HPV testing and cervical cytology in routine clinical practice. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] D. Smith,et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Motzer,et al. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] K. Flaherty,et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Iafrate,et al. Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] K. Aldape,et al. RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] K. McGlynn,et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. , 2010, Blood.
[13] D. Matei,et al. Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[15] Daniel L. Koller,et al. Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Herridge. NFKBIA Deletion in Glioblastomas , 2011 .
[17] R. Advani,et al. Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma , 2010 .
[18] T. Whelan,et al. NCIC CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[20] J. Yi,et al. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Thomas J. Smith,et al. American society of clinical oncology statement: toward individualized care for patients with advanced cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] E. Winer,et al. American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Scott D Ramsey,et al. A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. , 2010, Journal of the National Cancer Institute.
[24] J. Blay,et al. PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-An EORTC STBSG Global Network Study (EORTC 62072). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. Dipersio,et al. Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] N. Keating,et al. Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Scott E. Smith,et al. Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma , 2010 .
[28] K Miller,et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] C. Gridelli,et al. PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Loh,et al. Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] A. Oza,et al. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Xianglin L. Du,et al. Racial disparities in the use of hospice services according to geographic residence and socioeconomic status in an elderly cohort with nonsmall cell lung cancer , 2011, Cancer.
[33] Zev A. Binder,et al. The Genetic Landscape of the Childhood Cancer Medulloblastoma , 2011, Science.
[34] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[35] R. Kurzrock,et al. Personalized medicine in a phase I clinical trials program: The M. D. Anderson Cancer Center Initiative. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] D. Amadori,et al. Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] A. Novetsky,et al. Ovarian cancer care for the underserved: Are surgical patterns of care different in a public hospital setting? , 2011, Cancer.
[38] David C. Miller,et al. Hospice use and high-intensity care in men dying of prostate cancer. , 2011, Archives of internal medicine.
[39] M. Garami,et al. Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] John P Leonard,et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. , 2010, The New England journal of medicine.
[41] T. Barbui,et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] C. Rudin,et al. Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] G. Giaccone,et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] D. Heo,et al. Impact of awareness of terminal illness and use of palliative care or intensive care unit on the survival of terminally ill patients with cancer: prospective cohort study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] E. Wardelmann,et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.